SGLT2 inhibitors also proved renal protection by improving hemodynamics and reducing glomerular hyperfiltration, thereby slowing the progression of diabetic kidney disease and indirectly reducing cardiovascular and all-cause mortality rates [47,48]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.